These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 38842323

  • 1. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C.
    Antimicrob Agents Chemother; 2024 Jul 09; 68(7):e0053624. PubMed ID: 38842323
    [Abstract] [Full Text] [Related]

  • 2. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K, TB-PRACTECAL team.
    Lancet Respir Med; 2024 Feb 09; 12(2):117-128. PubMed ID: 37980911
    [Abstract] [Full Text] [Related]

  • 3. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan.
    Lin CJ, Chen JH, Chien ST, Huang YW, Lin CB, Lee JJ, Lee CH, Yu MC, Chiang CY.
    J Microbiol Immunol Infect; 2024 Oct 09; 57(5):791-800. PubMed ID: 39160114
    [Abstract] [Full Text] [Related]

  • 4. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT.
    Trials; 2022 Jun 13; 23(1):484. PubMed ID: 35698158
    [Abstract] [Full Text] [Related]

  • 5. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 13; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep 13; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [Abstract] [Full Text] [Related]

  • 9. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM, Radtke KK, Hesseling AC, Winckler J, Schaaf HS, Draper HR, Solans BP, van der Laan L, Hughes J, Fourie B, Nielsen J, Garcia-Prats AJ, Savic RM.
    Antimicrob Agents Chemother; 2023 Jul 18; 67(7):e0144822. PubMed ID: 37358463
    [Abstract] [Full Text] [Related]

  • 10. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 18; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 11. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R, Ma JB, Yang H, Yang H, Yang XJ, Wu YQ, Ren F.
    Microbiol Spectr; 2023 Aug 17; 11(4):e0104823. PubMed ID: 37310268
    [Abstract] [Full Text] [Related]

  • 12. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK.
    Int J Tuberc Lung Dis; 2022 Apr 01; 26(4):334-340. PubMed ID: 35351238
    [Abstract] [Full Text] [Related]

  • 13. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F, Gao J, Gao M, Liu Y, Shu W, Xie L, Sun Y, Zhang L, Li L, Pang Y.
    Antimicrob Agents Chemother; 2022 Sep 20; 66(9):e0203321. PubMed ID: 36047781
    [Abstract] [Full Text] [Related]

  • 14. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M.
    BMC Med; 2024 Sep 19; 22(1):401. PubMed ID: 39300460
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. T-wave morphology abnormalities in the STREAM stage 1 trial.
    Hughes G, Young WJ, Bern H, Crook A, Lambiase PD, Goodall RL, Nunn AJ, Meredith SK.
    Expert Opin Drug Saf; 2024 Apr 19; 23(4):469-476. PubMed ID: 38462751
    [Abstract] [Full Text] [Related]

  • 18. ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?
    Hughes G, Bern H, Chiang CY, Goodall RL, Nunn AJ, Rusen ID, Meredith SK.
    Int J Tuberc Lung Dis; 2022 Nov 01; 26(11):1065-1070. PubMed ID: 36281045
    [Abstract] [Full Text] [Related]

  • 19. Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis.
    Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, Conradie F, Howell P, Padanilam X, Ferreira H, Variaiva E, Rajaram S, Gupta A, Juneja S, Ndjeka N.
    PLoS One; 2024 Nov 01; 19(10):e0309034. PubMed ID: 39432463
    [Abstract] [Full Text] [Related]

  • 20. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R, Singla N, Vohra V, Singla R, Puri MM, Munjal S, Khalid UK, Myneedu VP, Kumar Verma A, Mathuria KK.
    Indian J Tuberc; 2019 Jan 01; 66(1):209-213. PubMed ID: 30878071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.